Palantir’s Civilian Push Hits a Political Snag in the UK Just as a $300 Million USDA Deal Lands

Palantir secures $300M USDA deal for agricultural modernization, but its £330M NHS contract faces early termination amid data privacy concerns. Stock down 16% YTD ahead of Q1 earnings.

Palantir Technologies is navigating a tale of two continents. On one side, a freshly inked $300 million framework agreement with the U.S. Department of Agriculture signals the company’s deepening pivot to civilian government work. On the other, a £330 million contract with Britain’s National Health Service faces the real possibility of an early termination, as political pressure over data privacy and software ownership intensifies.

The USDA deal, announced ahead of the company’s first-quarter earnings release on May 4, tasks Palantir with modernizing the agency’s national action plan for agricultural security. At its core is the “One Farmer, One File” initiative, which aims to give American farmers a unified digital profile. The project consolidates outdated IT systems across the department, reduces administrative burdens for field agents, and shores up the resilience of domestic food supply chains against fraud and foreign interference. Palantir will deploy its “Landmark” platform to integrate the disparate systems.

Across the Atlantic, the mood is less celebratory. The Metropolitan Police in London is exploring a major expansion of its use of Palantir’s software to automate crime-data analysis, building on existing experimental tools used to detect internal misconduct. But the bigger prize—the NHS contract valued at £330 million—is under direct threat. Health Minister Zubir Ahmed has not ruled out switching to a competitor, and an exit clause becomes available in spring 2027. Parliamentary critics, led by committee chair Chi Onwurah, have labeled concerns over data protection and the NHS’s lack of software rights after the contract ends as “legitimate and substantial,” pushing back against Palantir’s characterization of the opposition as purely ideological.

Despite the political headwinds in Europe, institutional investors are showing confidence. Vanguard recently expanded its stake by roughly 1.5 million shares, now holding just over 9% of the company. AQR Capital Management has also increased its position. In total, nearly 46% of outstanding shares are now in institutional hands. This professional backing provides a cushion for a stock that has fallen about 16% year-to-date to trade near €120, roughly 15% below its 200-day moving average.

The earnings report due Monday after the U.S. market close will be a critical test. Wall Street expects first-quarter revenue of $1.54 billion, representing 74% growth year-over-year. Management’s full-year guidance calls for around $7.2 billion in sales, a 61% increase, fueled by surging U.S. commercial revenue—which more than doubled in the fourth quarter—and a 66% jump in government income. The DZ Bank has initiated coverage with a buy rating and a $175 price target, citing the rare combination of rapid growth and high profitability.

Yet the stock’s valuation leaves no room for error. At roughly 110 times forward earnings, Palantir trades about 30% below its all-time high. Analysts caution that any miss on the consensus estimates could send shares toward the 52-week low near €96. For a company juggling a landmark USDA win with a wobbling NHS contract, the next few days will determine whether the market focuses on the prize or the peril.